Search Results - "Allen, Joshua E"

A Bayesian machine learning approach for drug target identification using diverse data types by Madhukar, Neel S., Khade, Prashant K., Huang, Linda, Gayvert, Kaitlyn, Galletti, Giuseppe, Stogniew, Martin, Allen, Joshua E., Giannakakou, Paraskevi, Elemento, Olivier

“…Drug target identification is a crucial step in development, yet is also among the most complex. To address this, we develop BANDIT, a Bayesian…”
Get full text

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner by Prabhu, Varun V, Allen, Joshua E, Dicker, David T, El-Deiry, Wafik S

“…Self-renewing colorectal cancer stem/progenitor cells (CSC) contribute to tumor maintenance and resistance to therapy. Therapeutic targeting of CSCs could…”
Get full text

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy by Prabhu, Varun Vijay, Morrow, Sara, Rahman Kawakibi, Abed, Zhou, Lanlan, Ralff, Marie, Ray, Jocelyn, Jhaveri, Aakash, Ferrarini, Isacco, Lee, Young, Parker, Cassandra, Zhang, Yiqun, Borsuk, Robyn, Chang, Wen-I, Honeyman, Joshua N., Tavora, Fabio, Carneiro, Benedito, Raufi, Alexander, Huntington, Kelsey, Carlsen, Lindsey, Louie, Anna, Safran, Howard, Seyhan, Attila A., Tarapore, Rohinton S., Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, El-Deiry, Wafik S.

“…ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of…”
Get full text

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma by Arrillaga-Romany, Isabel, Chi, Andrew S, Allen, Joshua E, Oster, Wolfgang, Wen, Patrick Y, Batchelor, Tracy T

“…ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via…”
Get full text

Leveraging external data in the design and analysis of clinical trials in neuro-oncology by Rahman, Rifaquat, Ventz, Steffen, McDunn, Jon, Louv, Bill, Reyes-Rivera, Irmarie, Polley, Mei-Yin C, Merchant, Fahar, Abrey, Lauren E, Allen, Joshua E, Aguilar, Laura K, Aguilar-Cordova, Estuardo, Arons, David, Tanner, Kirk, Bagley, Stephen, Khasraw, Mustafa, Cloughesy, Timothy, Wen, Patrick Y, Alexander, Brian M, Trippa, Lorenzo

“…Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in…”
Get full text

Role of Dopamine Receptors in the Anticancer Activity of ONC201 by Kline, Christina Leah B., Ralff, Marie D., Lulla, Amriti R., Wagner, Jessica M., Abbosh, Phillip H., Dicker, David T., Allen, Joshua E., El-Deiry, Wafik S.

“…ONC201/TIC10 is a first-in-class small molecule inducer of TRAIL that causes early activation of the integrated stress response. Its promising safety profile…”
Get full text

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects by Allen, Joshua E, Krigsfeld, Gabriel, Mayes, Patrick A, Patel, Luv, Dicker, David T, Patel, Akshal S, Dolloff, Nathan G, Messaris, Evangelos, Scata, Kimberly A, Wang, Wenge, Zhou, Jun-Ying, Wu, Gen Sheng, El-Deiry, Wafik S

“…Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an antitumor protein that is in clinical trials as a potential anticancer…”
Get more information

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies by Ishizawa, Jo, Kojima, Kensuke, Chachad, Dhruv, Ruvolo, Peter, Ruvolo, Vivian, Jacamo, Rodrigo O, Borthakur, Gautam, Mu, Hong, Zeng, Zhihong, Tabe, Yoko, Allen, Joshua E, Wang, Zhiqiang, Ma, Wencai, Lee, Hans C, Orlowski, Robert, Sarbassov, Dos D, Lorenzi, Philip L, Huang, Xuelin, Neelapu, Sattva S, McDonnell, Timothy, Miranda, Roberto N, Wang, Michael, Kantarjian, Hagop, Konopleva, Marina, Davis, R Eric, Andreeff, Michael

“…The clinical challenge posed by p53 abnormalities in hematological malignancies requires therapeutic strategies other than standard genotoxic chemotherapies…”
Get more information

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia by Nii, Takenobu, Prabhu, Varun V., Ruvolo, Vivian, Madhukar, Neel, Zhao, Ran, Mu, Hong, Heese, Lauren, Nishida, Yuki, Kojima, Kensuke, Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Charter, Neil, Deacon, Sean, Elemento, Olivier, Allen, Joshua E., Oster, Wolfgang, Stogniew, Martin, Ishizawa, Jo, Andreeff, Michael

“…Imipridones constitute a novel class of antitumor agents. Here, we report that a second-generation imipridone, ONC212, possesses highly increased antitumor…”
Get full text

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent by Allen, Joshua E, Crowder, Roslyn N, Crowder, Roslyn, El-Deiry, Wafik S

“…We previously identified ONC201 (TIC10) as a first-in-class orally active small molecule with robust antitumor activity that is currently in clinical trials in…”
Get full text

Regulation of the human TRAIL gene by Allen, Joshua E., El-Deiry, Wafik S.

“…TRAIL is a member of the TNF superfamily that induces tumor-selective cell death by engaging the pro-apoptotic death receptors DR4 and DR5. The antitumor…”
Get full text

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer by Paraghamian, Sarah E., Qiu, Jianqing, Hawkins, Gabrielle M., Zhao, Ziyi, Sun, Wenchuan, Fan, Yali, Zhang, Xin, Suo, Hongyan, Hao, Tianran, Prabhu, Varun Vijay, Allen, Joshua E., Zhou, Chunxiao, Bae-Jump, Victoria

“…Poly ADP-ribose polymerase (PARP) inhibitors are effective therapies for cancer patients with homologous recombination (HR) deficient tumors. The imipridone…”
Get full text

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 by Wagner, Jessica, Kline, Christina Leah, Ralff, Marie D, Lev, Avital, Lulla, Amriti, Zhou, Lanlan, Olson, Gary L, Nallaganchu, Bhaskara Rao, Benes, Cyril H, Allen, Joshua E, Prabhu, Varun V, Stogniew, Martin, Oster, Wolfgang, El-Deiry, Wafik S

“…Anti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation…”
Get full text

Discovery and clinical introduction of first-in-class imipridone ONC201 by Allen, Joshua E, Kline, C Leah B, Prabhu, Varun V, Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L, Pottorf, Richard S, Nallaganchu, B Rao, Olson, Gary L, Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T, Talekar, Mala K, Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L, Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S

“…ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced…”
Get full text

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer by Pierce, Stuart R, Fang, Ziwei, Yin, Yajie, West, Lindsay, Asher, Majdouline, Hao, Tianran, Zhang, Xin, Tucker, Katherine, Staley, Allison, Fan, Yali, Sun, Wenchuan, Moore, Dominic T, Xu, Chang, Tsai, Yi-Hsuan, Parker, Joel, Prabhu, Varun Vijay, Allen, Joshua E, Lee, Douglas, Zhou, Chunxiao, Bae-Jump, Victoria

“…ONC201 is a dopamine receptor D2 (DRD2) antagonist that inhibits tumor growth in preclinical models through ClpP activation to induce integrated stress…”
Get full text

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells by Amoroso, Francesca, Glass, Kimberley, Singh, Reema, Liberal, Francisco, Steele, Rebecca E., Maguire, Sarah, Tarapore, Rohinton, Allen, Joshua E., Van Schaeybroeck, Sandra, Butterworth, Karl T., Prise, Kevin, O’Sullivan, Joe M., Jain, Suneil, Waugh, David J., Mills, Ian G.

“…Prostate cancer (PCa) is the most common non-cutaneous cancer in men and a notable cause of cancer mortality when it metastasises. The unfolded protein…”
Get full text

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors by Prabhu, Varun V, Lulla, Amriti R, Madhukar, Neel S, Ralff, Marie D, Zhao, Dan, Kline, Christina Leah B, Van den Heuvel, A Pieter J, Lev, Avital, Garnett, Mathew J, McDermott, Ultan, Benes, Cyril H, Batchelor, Tracy T, Chi, Andrew S, Elemento, Olivier, Allen, Joshua E, El-Deiry, Wafik S

“…Cancer stem cells (CSCs) correlate with recurrence, metastasis and poor survival in clinical studies. Encouraging results from clinical trials of CSC…”
Get full text

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10 by Allen, Joshua E, Prabhu, Varun V, Talekar, Mala, van den Heuvel, A Pieter J, Lim, Bora, Dicker, David T, Fritz, Jennifer L, Beck, Adam, El-Deiry, Wafik S

“…ONC201/TIC10 is a small-molecule inducer of the TRAIL gene under current investigation as a novel anticancer agent. In this study, we identify critical…”
Get full text

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro by Zhang, Yingao, Huang, Yu, Yin, Yajie, Fan, Yali, Sun, Wenchuan, Zhao, Xiaoling, Tucker, Katherine, Staley, Allison, Paraghamian, Sarah, Hawkins, Gabrielle, Prabhu, Varun, Allen, Joshua E., Zhou, Chunxiao, Bae-Jump, Victoria

“…ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being…”
Get full text

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer by Fan, Yali, Wang, Jiandong, Fang, Ziwei, Pierce, Stuart R, West, Lindsay, Staley, Allison, Tucker, Katherine, Yin, Yajie, Sun, Wenchuan, Kong, Weimin, Prabhu, Varun, Allen, Joshua E, Zhou, Chunxiao, Bae-Jump, Victoria L

“…ONC201 is a promising first-in-class small molecule that has been reported to have anti-neoplastic activity in various types of cancer through activation of…”
Get full text